Abich Financial Wealth Management LLC Makes New $626,000 Investment in Gilead Sciences, Inc. $GILD

Abich Financial Wealth Management LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,639 shares of the biopharmaceutical company’s stock, valued at approximately $626,000. Gilead Sciences makes up 0.2% of Abich Financial Wealth Management LLC’s investment portfolio, making the stock its 25th biggest holding.

A number of other large investors also recently modified their holdings of GILD. GoalVest Advisory LLC grew its position in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $26,000. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at $27,000. Putney Financial Group LLC grew its holdings in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new position in Gilead Sciences in the 2nd quarter worth $30,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Wolfe Research upped their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday. Mizuho increased their target price on Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Oppenheimer raised their price target on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday. Argus lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Cantor Fitzgerald boosted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday. Twenty-three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $152.42.

Gilead Sciences Trading Down 2.6%

NASDAQ:GILD opened at $151.81 on Friday. The firm has a market capitalization of $188.35 billion, a P/E ratio of 22.42, a PEG ratio of 0.81 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The company’s 50-day simple moving average is $129.59 and its 200 day simple moving average is $121.98.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period last year, the business earned $1.90 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is presently 46.68%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the transaction, the chief executive officer owned 613,912 shares in the company, valued at $92,086,800. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. This trade represents a 1.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 319,391 shares of company stock valued at $44,141,101. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.